Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.440
-0.080 (-1.45%)
Streaming Delayed Price
Updated: 12:24 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
Next >
Thinking of Buying Biotech Stocks? Do These 3 Things First
March 22, 2023
It's better to plan ahead than to get caught by surprise.
Via
The Motley Fool
Editas Medicine Earnings Preview
February 21, 2023
Via
Benzinga
These 2 Biotech Stocks Could Soar in the Next Bull Market
February 17, 2023
They're both at the cutting edge of gene-editing technology.
Via
The Motley Fool
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
February 16, 2023
Which of these rebounding biotech stocks is the better buy right now?
Via
The Motley Fool
Top CRISPR Stocks
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
3 No-Brainer Stocks to Buy Right Now for Less Than $25
February 04, 2023
All three healthcare stocks are showing solid long-term potential.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
Why Editas Medicine Stock Charged Higher in January
February 02, 2023
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.
Via
The Motley Fool
Expert Ratings for Editas Medicine
February 01, 2023
Via
Benzinga
Why Shares of Editas Medicine Jumped This Week
January 26, 2023
It's been a seesaw month for the clinical-stage gene-editing biotech.
Via
The Motley Fool
Is Editas Medicine Stock a Buy Now?
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
February 02, 2023
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.
Via
InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
Via
Benzinga
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
January 19, 2023
Via
Benzinga
Analyst Expectations for Editas Medicine's Future
January 10, 2023
Via
Benzinga
Why Editas Medicine Stock Is Sliding Today
January 09, 2023
The gene-editing pioneer announced a big shake-up with its research and development programs.
Via
The Motley Fool
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
January 18, 2023
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.
Via
InvestorPlace
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Analyst Ratings for Editas Medicine
December 06, 2022
Via
Benzinga
2 Beaten-Down Stocks to Watch Closely Next Year
December 06, 2022
These biotechs could skyrocket in 2023, but only if they can execute their plans.
Via
The Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
December 06, 2022
Via
Benzinga
Why Shares of Editas Medicine Dropped 15.5% in November
December 05, 2022
The biotech's shares plummeted after it paused a key clinical trial.
Via
The Motley Fool
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
The company could continue lagging the market for a while.
Via
The Motley Fool
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
November 18, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
Upgrades
Via
Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
November 18, 2022
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell...
Via
Benzinga
Intuit To $490? Here Are 5 Other Price Target Changes For Friday
November 18, 2022
Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on...
Via
Benzinga
Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50%
November 18, 2022
Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.